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Despite the necessity for studies of group B streptococci
(GBS), due to the increase in serious adult infections, the
emergence of new serotypes, and the increased resistance to
macrolide antibiotics, such studies have been limited in Korea.
The primary purpose of the present study was to determine the
frequency trends of GBS serotypes, including serotypes VI,
VII, and VIII. The final objective was to elucidate the relation-
ship between the genotypes and serotypes of macrolide-resis-
tant GBS isolates from a Korean population. Among 446
isolates of Streptococcus agalactiae, isolated between January
1990 and December 2002 in Korea, the frequency of serotypes
were III (36.5%), Ib (22.0%), V (21.1%), Ia (9.6%), VI (4.3%),
II (1.8%), VIII (1.3%), IV (1.1%), and VII (0.9%). The resis-
tance rates to erythromycin, by serotype, were 85% (V), 23%
(III), 21% (VI), 3% (Ib), and 2% (Ia). Of 135 erythromycin-
resistant S. agalactiae, ermB was detected in 105 isolates,
mefA in 20 isolates, and ermTR in seven isolates; most type
V isolates harbored the ermB gene, Ib type isolates had an
equal distribution of resistance genes, type III isolates
accounted for 70% of all isolates carrying mefA genes, and one
fourth of type VI isolates had mefA genes.
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INTRODUCTION
Streptococcus agalactiae (group B streptococci,
GBS) is still susceptible to penicillin but has
shown an increasing resistance to erythromycin
and clindamycin during the last decade in many
parts of the world.
1-5 In Korea, resistance rates to
erythromycin and clindamycin among isolates of
GBS have been increasing.
6 As determined in our
previous studies,
7,8 the rates of erythromycin and
clindamycin resistance among GBS isolates have
increased from 0% in 1990-1995 to 41% in 2002,
and 0% in 1990-1993 to 48% in 2002, respectively.
Over the past decade, several investigators have
reported that an increasing proportion of GBS
disease is due to serotype V organisms.
4,5,9,10 In
addition, several reports documented an associa-
tion between macrolide resistance and GBS
serotype V.
5,9,11,12 Strains of serotypes IV, VI, VII,
and VIII have rarely been isolated from patients
in the United States and Europe.
13 However, the
emergence of new serotypes has been reported in
Japan.
14 In our previous study,
12 it was deter-
mined that the proportion of non-typeable (NT)
serotypes was increasing among GBS. The aims of
this study were to investigate the distribution of
GBS serotypes, including new types by year of
isolation, and to elucidate the correlation between
serotypes and genotypes of macrolide-resistant S.
agalactiae in a Korean population.
MATERIALS AND METHODS
The GBS isolates in this study were collected
between January 1990 and December 2002 at
Wonju Christian Hospital, a university hospital in
South Korea. Pure isolates of 138 GBS (2001-2002)
and 24 non-typeable GBS (1990-2000) were tested
for serotyping. The results of antimicrobial sus-
ceptibilities, phenotypes, and genotypes of ery-
thromycin-resistant GBS isolates were adopted
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from our previous data.
7,8,12 Serotypes Ia, Ib, and
II-V were determined by use of Hemolytic Strep-
tococcus Group B Typing Sera (Denka Seiken Co.,
Ltd., Tokyo, Japan), and serotypes VI-VIII were
serotyped with coagglutination (ESSUM Group B
Streptococcus Serotyping Test; Bacterum AB,
Umeå, Sweden).
RESULTS
The overall serotype frequencies of the 446 GBS
isolates were III (36.5%), Ib (22.0%), V (21.1%), Ia
(9.6%), VI (4.3%), II (1.8%), VIII (1.3%), IV (1.1%),
and VII (0.9%). In our hospital between 1990 and
1995, Ib was the most common serotype, followed
by serotypes III and Ia; III was by far the most
common serotype from 1996 to 2000. Serotype V
was not detected before 1996; it was the most
common serotype from 2001 to 2002. Serotype VI
did not exist before 1997. Since then, its frequency
ranged from 2.5% to 9.1%. In this hospital,
Serotypes II, IV, VII, and VIII were rarely isolated
(Table 1).
The overall resistance rates to erythromycin,
clindamycin, and tetracycline were 30%, 35%, and
96%, respectively (Table 2).
Among the 135 erythromycin-resistant strains in
this study, ermB was detected in 105 strains
(77.8%); mefA in 20 strains (14.8%); and ermTR in
Table 1. Isolation Frequency of Serotypes of S. agalactiae by Year
Year
Serotypes
Total
Ia Ib II III IV V VI VII VIII NT*
1990 1 3 0 2 0 0 0 0 0 0 6
1991 0 3 1 1 0 0 0 0 0 0 5
1992 1 8 0 3 0 0 0 0 0 0 12
1993 0 0 1 2 0 0 0 0 0 0 3
1994 1 6 0 5 0 0 0 0 1 0 13
1995 1 4 0 2 0 0 0 0 0 0 7
1996 4 17 2 22 0 3 0 1 0 1 50
1997 7 15 0 15 0 9 2 0 0 0 48
1998 2 9 1 20 0 5 1 0 0 2 40
1999 6 8 0 26 3 10 2 1 1 1 58
2000 5 8 0 22 1 19 6 2 2 1 66
2001 7 12 0 28 1 32 4 0 0 1 85
2002 8 5 3 15 0 16 4 0 2 0 53
Total 43 98 8 163 5 94 19 4 6 6 446
*NT, not-typeable.
Table 2. Rates of Antimicrobial Resistance of S. agalactiae by Serotypes
Antimicrobials
No.(%) of resistance isolates of serotype
Ia
[43]
Ib
[98]
II
[8]
III
[163]
IV
[5]
V
[94]
VI
[19]
VII
[4]
VIII
[6]
NT*
[6]
Total
[446]
Erythromycin 1 (2) 3 (3) 1 (13) 38 (23) 3 (60) 80 (85) 4 (21) 0 (0) 3 (50) 2 (33) 135 (30)
Clindamycin 6 (14) 11 (11) 1 (13) 47 (29) 3 (60) 80 (85) 1 (5) 0 (0) 4 (67) 3 (50) 156 (35)
*NT, not-typeable.
The numbers in brackets mean the total No. of GBS isolates by serotype.
All GBS isolates in this study were susceptible to penicillin, ceftriaxone, and vancomycin.Young Uh, et al.
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seven strains (5.2%). The most prevalent serotypes
of erythromycin-resistant GBS isolates were V
(n=80, 59.3%) and III (n=38, 28.1%) (Table 3).
DISCUSSION
A recent study in Japan showed that serotypes
VIII (36%) and VI (25%) were the most common
serotypes in healthy pregnant women.
14 Matsuura
et al.
15 also reported that 28.6% to 35.3% of GBS
isolated from the sputum of elderly patients were
serotype VIII. In throat isolates from school chil-
dren, Okuyama et al.
16 reported that Ia was domi-
nant from 1980 to 1988, III from 1989 to 1990, and
VI from 1991 to 1992. In Korea, Lee et al.
6 re-
ported that serotypes VI and VIII were not
detected from 1979 to 1992, but from 1993 to 1996,
the proportions of VI and VIII serotypes were 3%
(6/200) and 2% (4/200), respectively. Serotype VI
and VIII strains were known to be less virulent.
However, Ekelund et al.
17 recently reported that
serotype VIII constituted 6% of all of the invasive
GBS infections in Denmark. The differences in
serotype distribution among various populations
also may reflect differences in pathogenesis
among the serotypes. Therefore, monitoring the
serotype distribution of all nine serotypes is im-
portant for complete surveillance of GBS infec-
tions and for vaccine formulation.
The resistance rates to erythromycin found for
our common serotypes (> 10 isolates) were (in
decreasing order): 85% (V), 23% (III), 21% (VI), 3%
(Ib), and 2% (Ia). These results were consistent
with most other reports,
11,18 although some re-
searchers
1,19 reported that serotype Ib had a lower
rate of susceptibility to erythromycin than did
serotype Ia, III, or V isolates. The resistance rates
to clindamycin of our serotype Ia, Ib, and III
isolates were higher than those of erythromycin
while the other serotypes, with the exception of
serotype VI, had nearly equal susceptible rates to
erythromycin and clindamycin. Our results show
that resistance to clindamycin is more common
than resistance to erythromycin, and similar re-
sults were reported in Taiwan
1 and New Zealand.
20
The distribution of MLSB (macrolide-lincosamide-
streptogramin B) resistance genes and the isola-
tion frequency of serotypes of GBS may be major
factors contributing to differences in erythromycin
and clindamycin resistance in different countries.
Malbruny et al.
20 recently reported that a new LSA
(lincosamide-streptogramin A) phenotype was
noted in erythromycin-susceptible, clindamycin-
resistant S. agalactiae isolates from New Zealand
and that III (13/19) and I (5/19) were main the
serotypes of GBS with an LSA phenotype. Further
studies are needed to characterize our erythro-
mycin-susceptible, clindamycin-resistant GBS iso-
lates.
The distribution of MLSB resistance genes of
GBS is influenced by geographical variation and
serotypes and also changes with time. Among the
erythromycin-resistant isolates in this study, most
serotype V isolates harbored the ermB gene,
serotype Ib isolates had an equal distribution of
resistance genes, and serotype III isolates
accounted for 70% of GBS carrying mefA genes. Of
Table 3. Resistance Phenotypes and Genotypes of Erythromycin of S. agalactiae According to Serotypes
Phenotypes and genotypes
No. of serotypes
Total (%)
Ia Ib II III IV V VI VII VIII NT
ERY-I/R ermB 0 1 0 20 3 77 1 0 3 0 105 (23.5)
ermTR 0 1 1 3 0 1 0 0 0 1 7 (1.6)
mefA 1 1 0 14 0 0 3 0 0 1 20 (4.5)
ND 0 0 0 1 0 2 0 0 0 0 3 (0.7)
ERY-S, CLI-S 36 86 7 105 2 14 15 4 2 3 274 (61.4)
ERY-S, CLI-I/R 6 9 0 20 0 0 0 0 1 1 37 (8.3)
Total 43 98 8 163 5 94 19 4 6 6 446 (100)
Abbreviations: NT, not-typeable; ERY-I/R, erythromycin intermediate or resistant; ND, not detected; ERY-S, erythromycin susceptible;
CLI-S, clindamycin susceptible; CLI-I/R, clindamycin intermediate or resistant.Serotypes and Genotypes of GBS
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new serotypes with erythromycin-resistant genes,
25% of type VI isolates had mefA genes, 100% of
type VIII isolates had ermB genes, and type VII
isolates did not carry any resistance genes.
In conclusion, the high resistance rates to eryth-
romycin and clindamycin among our GBS isolates
were primarily due to a continued emergence of
serotype V GBS with the ermB gene. Serotype VI
isolates showed an increasing frequency trend in
our hospital. Further studies are required to ob-
serve any change in the trends of serotype distri-
bution and antimicrobial susceptibilities.
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